BCRX
BUYMeanRevComposite
69.20
Technical
47.10
Fundamental
76.60
Rank
—
Price
9.07
Hurst
0.25
As of
Aug 6, 2026
Daily
BioCryst Pharmaceuticals, Inc.
HealthcareDrug Manufacturers - Specialty & GenericBioCryst Pharmaceuticals is a biotechnology company focused on treatments for hereditary angioedema and other uncommon conditions. The company currently sells peramivir injection for influenza treatment under multiple brand names and ORLADEYO, an oral medication for hereditary angioedema. BioCryst also has several drugs in development for conditions including netherton syndrome, diabetic macular edema, and atopic dermatitis, along with partnerships with pharmaceutical firms and research institutions.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
9.26
PEG ratio
9.39
Dividend yield
—
Beta
0.56
52w range
6.00 – 11.22
Return on equity
—
Profit margin
-40.90%
Revenue growth
+33.60%
Earnings growth
+1400.00%
Price history
1Y: 8.70 (+9.3%) · range 6.24–11.11
Cycle position
27/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 67 · GOOD SETUP · exit proximity 0
Conviction
46/ 100 · maturity 100%
VScore.4017
Buildup.2053
EMA entry setup.2567
Fundamentals.1577
Volume profile
POC
9.75
Price vs POC
-10.7%
Overhead supply
81%
Runway
+2.5%
Value area 8.61–9.99 · 81% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.083 | Sep 15, 2026 |
| earnings-surprise | 0.033 | Sep 3, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +8.49% | +13.87% | mature |
| 40d | -12.69% | +13.87% | 25/40d |